Sign inJoin waitlistJoin the waitlist

Monica Goldklang

Director, Alpha-1 Foundation and Clinical Resource Center at Columbia University · New York Presbyterian Hospital

Credentials: · · · · · ·

History

Columbia Univ Coll of Phys & Surgeons
Present
Columbia Univ Coll of Phys & Surgeons
Present

Pulmonary Disease and Critical Care Medicine
New York Presbyterian Hospital
2008–2011
Internal Medicine
University of Michigan
2005–2008
University of Michigan Medical School
2001–2005

Research

Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice
Nature Medicine · 2016 · 213 citations
Biased Generation and In Situ Activation of Lung Tissue-Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma
The Journal of Immunology · 2018 · 109 citations
The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice
Blood · 2011 · 59 citations

Jeanine D'Armiento
27 papers
Adam Gerber
4 papers · 1 as a fellow
Igor Barjaktarevic
4 papers
Bradley Drummond
3 papers
James Wells
3 papers
Andrew Wilson
2 papers
Ginger Clark
2 papers
RS
Robert Sandhaus
2 papers
Aaron Hakim
1 paper · 1 as a fellow
Abhiram Bhashyam
1 paper · 1 as a resident
Akiva Mintz
1 paper
Alice Vinogradsky
1 paper · 1 as a resident

Grants

Smoke Induced Alterations in Ion Channel Function
National Heart, Lung, and Blood Institute · K08
Contact PI · $787.9K · Columbia University Health Sciences
2015–2020

Clinical trials

PiMZ Longitudinal Cohort (PiMZ Logic)
Principal investigator · Recruiting
Columbia University
2025–2029
COPD Exacerbation Blood and Urine Biomarkers Study
Principal investigator · Terminated
Columbia University
2018–2021
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Site PI · Recruiting · Phase 3
Takeda
2024–2028
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Site PI · Recruiting · Phase 3
Takeda
2023–2031